Acknowledgements
A. Wegh-van der Schee, infections, P., T.L., W., Waardenburg, A. Fabra Garcia, A. Yang, T.
ADVERSE EVENT, INFECTIONS, MALARIA, MOORE
This study was funded by Bill and Melinda Gates Foundation through PATH’s Malaria Vaccine Initiative. We acknowledge and thank all study participants for their participation in this trial. We also acknowledge and thank our colleagues at the Department of Medical Microbiology, Radboudumc, for support in conducting the trial: A. Jansens, D. Smit, X. Z. Yap, K. Lanke, Y. van Waardenburg, A. Fabra Garcia, A. Yang, T. Roos, K. Vink, A. Corbeek. We are grateful for R. Stoter and W. Graumans, R. Heutink, J. Klaasen, A. Pouwelsen, L. Pelser-Posthumus, and J. Kuhnen of the Malaria Unit at the Radboud University Medical Center for generating NF135-infected mosquitoes for immunizations and challenge infections. We thank F. Stelma, C. Handgraaf, E. Driessen, P. Daemen, A. Wegh-van der Schee, and J.P. Verhave for reading many thick blood smears. We thank M. Smit for taking over many follow-ups. We thank our colleagues at the RTCCS: S. Houba, K. Saini, J. van Unnik, A. Rasing, E. Otters-van Bodegom, E. Lenssen, and E. Eggenhuizen. We thank the Safety Monitoring Committee: R.P. Pickkers, M. van Vugt, T.L. Richie. We thank A. van Laarhoven for acting as the trial’s independent expert. We are grateful to P. Houzé and L.A. Décosterd for help in measuring drug concentrations in participants’ plasma. We thank S. Elias-Smale for help assessing and caring for the participant who experienced a cardiac serious adverse event. We additionally thank members of PATH’s Malaria Vaccine Initiative for support in conducting the trial: R. King, A. Birkett, L. Mercer, M. Raine, D. Scott, T. Madenwald, S. Gregory, Y. Wu, V. Moore, K. Mertes, S. Shanahan, and T. Lutzenhiser.